Live Breaking News & Updates on Alimera sciences

Stay informed with the latest breaking news from Alimera sciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Alimera sciences and stay connected to the pulse of your community

Alimera Sciences (NASDAQ:ALIM) Stock Rating Upgraded by StockNews.com

Alimera Sciences (NASDAQ:ALIM – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday. Separately, Maxim Group initiated coverage on shares of Alimera Sciences in a report on Monday, March 25th. They set a “buy” rating and a $10.00 […]

United-states , Worth-venture-partners , News-ratings-for-alimera-sciences-daily , Capital-management , Alimera-sciences-inc , Alimera-sciences-stock-performance , Stonepine-capital-management , Maxim-group , Institutional-trading-of-alimera-sciences , Alimera-sciences , Alimera-sciences-company-profile

Alimera Sciences (NASDAQ:ALIM) Upgraded to Buy at StockNews.com

Alimera Sciences (NASDAQ:ALIM – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday. Separately, Maxim Group initiated coverage on shares of Alimera Sciences in a research report on Monday, March 25th. They set a “buy” rating and a $10.00 price target […]

United-states , News-ratings-for-alimera-sciences-daily , Capital-management , Worth-venture-partners , Alimera-sciences-inc , Stonepine-capital-management , Maxim-group , Institutional-trading-of-alimera-sciences , Alimera-sciences-trading , Alimera-sciences-company-profile , Alimera-sciences

Equities Research Analysts' Upgrades for April 22nd (ALIM, AVY, CBAN, CMI, CZNC, EOG, FL, GTY, HAL, HCA)

Equities Research Analysts' Upgrades for April 22nd (ALIM, AVY, CBAN, CMI, CZNC, EOG, FL, GTY, HAL, HCA)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

News-ratings-for-alimera-sciences-inc-daily , Equities-research-analyst , Northern-oil , Alimera-sciences-inc , Sm-energy , Nextera-energy , Park-national , Alimera-sciences , Getty-realty , Era-energy , First-financial

StockNews.com Lowers Alimera Sciences (NASDAQ:ALIM) to Hold

Alimera Sciences (NASDAQ:ALIM – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday. Separately, Maxim Group initiated coverage on Alimera Sciences in a research note on Monday, March 25th. They set a “buy” rating and a $10.00 price objective on the […]

United-states , Citadel-advisors , Northern-trust-corp , Alimera-sciences , Osaic-holdings-inc , Alimera-sciences-inc , Alimera-sciences-company-profile , Maxim-group , Tower-research-capital , Hedge-funds-weigh-in-on-alimera-sciences , Alimera-sciences-trading-down

Luckie & Company Acquires Marbury Creative Group

/PRNewswire/ -- Luckie & Company announces the acquisition of Marbury Creative Group (MCG), an Atlanta-based creative marketing agency recognized for its work...

John-gardner , Shelly-hoffman , Rob-marbury , Luckie-atlanta , Client-solutions-development , Alimera-sciences , Prnewswire-luckie-company , Marbury-creative-group , Glaxosmithkline , Spice-world-inc , Regions-bank , Spice-world

Investment Analysts' New Coverage for March 25th (ALAB, ALIM, ALLT, APVO, AVTE, BIOL, CBAY, CETX, CNET, CORR)

Investment Analysts' New Coverage for March 25th (ALAB, ALIM, ALLT, APVO, AVTE, BIOL, CBAY, CETX, CNET, CORR)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada , Jpmorgan-chase-co , Maxim-group , Park-city-group , Motorola-solutions , Wells-fargo-company , Liqtech-international , Jefferies-financial-group-inc , Corenergy-infrastructure-trust , Financial-services , Royal-bank

Investment Analysts' New Coverage for March 25th (ALAB, ALIM, ALLT, APVO, AVTE, BIOL, CBAY, CETX, CNET, CORR)

Investment Analysts’ new coverage for Monday, March 25th: Northland Securities initiated coverage on shares of Astera Labs (NASDAQ:ALAB). The firm issued an outperform rating and a $85.00 price target on the stock. Maxim Group began coverage on shares of Alimera Sciences (NASDAQ:ALIM). Maxim Group issued a buy rating and a $10.00 target price on the […]

Canada , Financial-services , Liqtech-international , Jefferies-financial-group-inc , Corenergy-infrastructure-trust , Wells-fargo-company , Motorola-solutions , Jpmorgan-chase-co , Maxim-group , Park-city-group , Royal-bank

Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update - Alimera Sciences (NASDAQ:ALIM)

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal

Alimera-sciences-inc , Alimera-sciences ,

For Retina Specialists, 2024 Is a Time to Try New Tools

This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.

Washington , United-states , West-virginia , Illinois , American , Iveric-bio , Abbvie-allergan , Genentech-roche , Pegcetacoplan-syfovre , Reginal-sanders , Samsung-bioepis , David-boyer

EyePoint Is Betting The Bank On EYP-1901 (NASDAQ:EYPT)

EyePoint Is Betting The Bank On EYP-1901 (NASDAQ:EYPT)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Alimera-sciences , Ocular-therapeutics , Upfront-payment , Amended-alimera-agreement ,